BERLIN — German pharmaceutical company BioNTech says it expects to receive the results of trials of its coronavirus vaccine in younger children by September.
BioNTech, which developed the first widely approved COVID-19 shot with U.S. partner Pfizer, has already submitted data from trials in children ages 12-15 to the U.S. Food and Drug Administration and plans to do so for the European Medicines Agency, which regulates drugs for use in the 27-nation European Union. .
The company said it expects results from trials in children ages 5-12 “as early as July” and in those younger than 5 in September.
BioNTech said requests for regulatory approval would depend on the results of the trials.
The company is one of the main suppliers of coronavirus vaccines in Europe and North America.